Loading...
| A02321 | Pages: 188 | Jan 2020 | 9900 Views | | |
| Author(s) : Sayali Shinde , Onkar Sumant | Tables: 87 | Charts: 43 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Prostate Cancer Treatment Market
Request Now !The global prostate cancer treatment market size was valued at $6,887 million in 2018, and is projected to reach $9,904 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.
Prostate cancer is a type of cancer in which abnormal cells grow & invade in uncontrolled manner in the prostate gland. In term of cancer-related mortality in men, prostate cancer ranks sixth and eleventh in term of loss of life from any disease. Treatments of prostate cancer include radiation, surgery, chemotherapy, biological therapy, and hormone therapy. There are various diagnostic & therapeutic products used in the treatment & management of prostate cancer such as prostatic adenocarcinoma, benign prostatic hyperplasia, small cell carcinoma, and others.
Get more information on this report : Request Sample Pages
Rise in geriatric population, increase in prevalence of prostate cancer, surge in generic products, rise in awareness among people regarding the treatment of prostate cancer, improved R&D investment by drug innovators, strong emerging pipeline drugs, and availability of new prostate cancer treatments are the major factors that drive the growth of the prostate cancer treatment market. In addition, increase in demand for prostate cancer treatment as well as management and rise in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings are other factors that contribute toward the growth of the market. Furthermore, untapped potential offered by the developing economies present lucrative opportunities for the growth of the market during the forecast period. However, prolonged treatment durations and poor demand for prostate cancer treatment drugs in underdeveloped countries are expected to hinder the growth of the market.
Prostate Cancer Treatment Market Segmentation
The prostate cancer treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, the market is categorized into chemotherapy, biological therapy, hormone therapy, and others. Depending on distribution channel, the market is classified into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Segment Review
Based on drug type, the market is categorized into chemotherapy, biological therapy, and hormone therapy. Presently hormone therapy dominates the global prostate cancer treatment market, and is anticipated to continue this trend throughout the forecast period. The key factors that drive the market growth include increase in prevalence of prostate cancer, surge in demand for hormone therapy drugs, availability of generic drugs, rise in geriatric population, increase in number of pharmaceutical companies, and rise in public awareness toward prostate cancer treatment across the globe.
Get more information on this report : Request Sample Pages
Based on distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Currently, the hospital pharmacies segment accounted for the majority of prostate cancer treatment market share, owing to strong presence of hospital pharmacies across the globe, increase in number of hospitalized prostate cancer patients, and convenience offered by hospital pharmacies. The online pharmacies is the fastest growing segment during the forecast period, owing to rise in awareness regarding online pharmacies, increase in number of internet users, and surge in preference for online purchasing of drugs over the traditional methods.
Get more information on this report : Request Sample Pages
Snapshot of Asia-Pacific Prostate Cancer Treatment Market
Asia-Pacific presents lucrative opportunities for the key players operating in the prostate cancer treatment market, owing to growth in awareness about prostate cancer treatment and rise in adoption of prostate cancer treatment products. Moreover, improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth. Some of the other factors such as surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, high population base, and high disposable incomes are expected to drive the growth of the prostate cancer treatment market in Asia-Pacific.
Get more information on this report : Request Sample Pages
The key players profiled in this report include Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson & Johnson, and Takeda Pharmaceutical Company Ltd.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Market player positioning, 2018
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of prostate cancer
3.4.1.2. Rise in in geriatric population
3.4.1.3. Increase in government expenditure on healthcare
3.4.2. Restraint
3.4.2.1. Adverse effects associated with the use prostate cancer treatment drugs
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.4.4. Impact analysis
CHAPTER 4: PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Hormone Therapy
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Biological Therapy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Chemotherapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
CHAPTER 5: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Drug stores & retail pharmacy
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Online pharmacy
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
CHAPTER 6: PROSTATE CANCER TREATMENT MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. prostate cancer treatment market, by drug type
6.2.2.1.2. U.S. prostate cancer treatment market, by distribution channel
6.2.2.2. Canada
6.2.2.2.1. Canada prostate cancer treatment market, by drug type
6.2.2.2.2. Canada prostate cancer treatment market, by distribution channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico prostate cancer treatment market, by drug type
6.2.2.3.2. Mexico prostate cancer treatment market, by distribution channel
6.2.3. North America market size and forecast, by drug type
6.2.4. North America market size and forecast, by distribution channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany prostate cancer treatment market, by drug type
6.3.2.1.2. Germany prostate cancer treatment market, by distribution channel
6.3.2.2. France
6.3.2.2.1. France prostate cancer treatment market, by drug type
6.3.2.2.2. France prostate cancer treatment market, by distribution channel
6.3.2.3. UK
6.3.2.3.1. UK prostate cancer treatment market, by drug type
6.3.2.3.2. UK prostate cancer treatment market, by distribution channel
6.3.2.4. Italy
6.3.2.4.1. Italy prostate cancer treatment market, by drug type
6.3.2.4.2. Italy prostate cancer treatment market, by distribution channel
6.3.2.5. Spain
6.3.2.5.1. Spain prostate cancer treatment market, by drug type
6.3.2.5.2. Spain prostate cancer treatment market, by distribution channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe prostate cancer treatment market, by drug type
6.3.2.6.2. Rest of Europe prostate cancer treatment market, by distribution channel
6.3.3. Europe market size and forecast, by drug type
6.3.4. Europe market size and forecast, by distribution channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan prostate cancer treatment market, by drug type
6.4.2.1.2. Japan prostate cancer treatment market, by distribution channel
6.4.2.2. China
6.4.2.2.1. China prostate cancer treatment market, by drug type
6.4.2.2.2. China prostate cancer treatment market, by distribution channel
6.4.2.3. Australia
6.4.2.3.1. Australia prostate cancer treatment market, by drug type
6.4.2.3.2. Australia prostate cancer treatment market, by distribution channel
6.4.2.4. India
6.4.2.4.1. India prostate cancer treatment market, by drug type
6.4.2.4.2. India prostate cancer treatment market, by distribution channel
6.4.2.5. South Korea
6.4.2.5.1. South Korea prostate cancer treatment market, by drug type
6.4.2.5.2. South Korea prostate cancer treatment market, by distribution channel
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific prostate cancer treatment market, by drug type
6.4.2.6.2. Rest of Asia-Pacific prostate cancer treatment market, by distribution channel
6.4.3. Asia-Pacific market size and forecast, by drug type
6.4.4. Asia-Pacific market size and forecast, by distribution channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil prostate cancer treatment market, by drug type
6.5.2.1.2. Brazil prostate cancer treatment market, by distribution channel
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia prostate cancer treatment market, by drug type
6.5.2.2.2. Saudi Arabia prostate cancer treatment market, by distribution channel
6.5.2.3. South Africa
6.5.2.3.1. South Africa prostate cancer treatment market, by drug type
6.5.2.3.2. South Africa prostate cancer treatment market, by distribution channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA prostate cancer treatment market, by drug type
6.5.2.4.2. Rest of LAMEA prostate cancer treatment market, by distribution channel
6.5.3. LAMEA market size and forecast, by drug type
6.5.4. LAMEA market size and forecast, by distribution channel
CHAPTER 7: COMPANY PROFILES
7.1. Astellas Pharma Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. AstraZeneca plc
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. Bayer AG.
7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Product portfolio
7.3.4. Business performance
7.3.5. Key strategic moves and developments
7.4. Bristol-Myers Squibb Company
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. F. Hoffmann-La Roche AG
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. Ferring Pharmaceuticals Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. GlaxoSmithKline Plc.
7.7.1. Company overview
7.7.2. Operating business segments
7.7.3. Product portfolio
7.7.4. Business performance
7.8. Ipsen Pharma
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Johnson & Johnson
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments: Global
7.10. Takeda Pharmaceutical Company Ltd
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
LIST OF TABLES
TABLE 01. GLOBAL PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 02. HORMONE THERAPY PROSTATE CANCER TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. BIOLOGICAL THERAPY PROSTATE CANCER TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. CHEMOTHERAPY PROSTATE CANCER TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. OTHERS PROSTATE CANCER TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. GLOBAL PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026 ($MILLION)
TABLE 07. HOSPITAL PHARMACY PROSTATE CANCER TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. DRUG STORES & RETAIL PHARMACY PROSTATE CANCER TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. ONLINE PHARMACY PROSTATE CANCER TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10. PROSTATE CANCER TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. NORTH AMERICA PROSTATE CANCER TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 12. U.S. PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 13. U.S. PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 14. CANADA PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 15. CANADA PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 16. MEXICO PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 17. MEXICO PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 18. NORTH AMERICA PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 19. NORTH AMERICA PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 20. EUROPE PROSTATE CANCER TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 21. GERMANY PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 22. GERMANY PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 23. FRANCE PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 24. FRANCE PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 25. UK PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 26. UK PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 27. ITALY PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 28. ITALY PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 29. SPAIN PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 30. SPAIN PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 31. REST OF EUROPE PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 32. REST OF EUROPE PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 33. EUROPE PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 34. EUROPE PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 35. ASIA-PACIFIC PROSTATE CANCER TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 36. JAPAN PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 37. JAPAN PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 38. CHINA PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 39. CHINA PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 40. AUSTRALIA PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 41. AUSTRALIA PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 42. INDIA PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 43. INDIA PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 44. SOUTH KOREA PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 45. SOUTH KOREA PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 46. REST OF ASIA-PACIFIC PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 47. REST OF ASIA-PACIFIC PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 48. ASIA-PACIFIC PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 49. ASIA-PACIFIC PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 50. LAMEA PROSTATE CANCER TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 51. BRAZIL PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 52. BRAZIL PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 53. SAUDI ARABIA PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 54. SAUDI ARABIA PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 55. SOUTH AFRICA PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 56. SOUTH AFRICA PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 57. REST OF LAMEA PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 58. REST OF LAMEA PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 59. LAMEA PROSTATE CANCER TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 60. LAMEA PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 61. ASTELLAS: COMPANY SNAPSHOT
TABLE 62. ASTELLAS: PRODUCT PORTFOLIO
TABLE 63. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 64. ASTRAZENECA: OPERATING BUSINESS SEGMENTS
TABLE 65. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 66. BAYER.: COMPANY SNAPSHOT
TABLE 67. BAYER.: OPERATING SEGMENTS
TABLE 68. BAYER.: PRODUCT PORTFOLIO
TABLE 69. BMS: COMPANY SNAPSHOT
TABLE 70. BMS: PRODUCT PORTFOLIO
TABLE 71. ROCHE: COMPANY SNAPSHOT
TABLE 72. ROCHE: OPERATING SEGMENTS
TABLE 73. ROCHE: PRODUCT PORTFOLIO
TABLE 74. FERRING: COMPANY SNAPSHOT
TABLE 75. FERRING: PRODUCT BUSINESS SEGMENT
TABLE 76. FERRING: PRODUCT PORTFOLIO
TABLE 77. GSK.: COMPANY SNAPSHOT
TABLE 78. GSK.: OPERATING BUSINESS SEGMENTS
TABLE 79. GSK.: PRODUCT PORTFOLIO
TABLE 80. IPSEN: COMPANY SNAPSHOT
TABLE 81. IPSEN: OPERATING SEGMENTS
TABLE 82. IPSEN: PRODUCT PORTFOLIO
TABLE 83. J&J: COMPANY SNAPSHOT
TABLE 84. J&J: OPERATING BUSINESS SEGMENTS
TABLE 85. J&J: PRODUCT PORTFOLIO
TABLE 86. TAKEDA: COMPANY SNAPSHOT
TABLE 87. TAKEDA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL PROSTATE CANCER TREATMENT MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET PLAYER POSITIONING, 2018
FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. MODERATE THREAT OF SUBSTITUTES
FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
FIGURE 08. HIGH INTENSITY OF RIVALRY
FIGURE 09. IMPACT ANALYSIS
FIGURE 10. COMPARATIVE ANALYSIS OF HORMONE THERAPY PROSTATE CANCER TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF BIOLOGICAL THERAPY PROSTATE CANCER TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF CHEMOTHERAPY PROSTATE CANCER TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF OTHERS PROSTATE CANCER TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF HOSPITAL PHARMACY PROSTATE CANCER TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS DRUG STORES & RETAIL PHARMACY PROSTATE CANCER TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF ONLINE PHARMACY PROSTATE CANCER TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. ASTELLAS: NET SALES, 2016–2018 ($MILLION)
FIGURE 18. ASTELLAS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 19. ASTELLAS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 20. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 21. ASTRAZENECA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 22. BAYER: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. BAYER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 24. BAYER: REVENUE SHARE BY REGION, 2018(%)
FIGURE 25. BMS: NET SALES, 2016–2018 ($MILLION)
FIGURE 26. BMS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 27. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 28. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 29. ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 30. FERRING: NET SALES, 2016–2018 ($MILLION)
FIGURE 31. FERRING: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 32. FERRING: REVENUE SHARE BY REGION, 2018(%)
FIGURE 33. GSK: NET SALES, 2016–2018 ($MILLION)
FIGURE 34. GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 35. GSK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 36. IPSEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 37. IPSEN: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 38. IPSEN: REVENUE SHARE BY REGION, 2018(%)
FIGURE 39. J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 41. J&J: REVENUE SHARE BY REGION, 2018(%)
FIGURE 42. TAKEDA: NET SALES, 2016–2018 ($MILLION)
FIGURE 43. TAKEDA: REVENUE SHARE BY REGION, 2018 (%)
Prostate cancer is a type of cancer that occurs in the prostate gland. It is one of the most common type of cancer in men. It is developed when cells in prostate gland starts multiplying uncontrollably. The average age of incidence is above 65 and rarely occurs below the age of 40. Treatments for prostate cancer include radiation therapy, surgery, and drug therapy. The drug therapy include chemotherapy, biological therapy, and hormone therapy.
Rise in prevalence of prostate cancer, technological advancements in prostate cancer treatment products, rise in number of pharmaceutical companies, strong emerging pipeline drugs, increase in popularity of hormone therapy drugs, and rise in demand for prostate cancer treatment products significantly boost the growth of the market. Moreover, rise in awareness among people regarding the treatments of prostate cancer, increase in number of generic products, surge in healthcare expenditure in the developed and developing regions, rise in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings, and improved R&D investment by drug innovators further fuel the growth of the global prostate cancer treatment market.
North America is expected to remain dominant during the forecast period, owing to higher adoption of prostate cancer treatment products with substantial presence of pharmaceutical and R&D laboratories. In addition, presence of advanced facilities and wide availability of advanced systems supplement the growth of the market. Moreover, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to developments in infrastructure of the pharmaceutical industries along with rise in demand for prostate cancer treatment products.
A. The market value of global prostate cancer treatment market was $6,887.3 million in 2018.
A. The forecast period is from 2019 to 2026.
A. The market value of global prostate cancer treatment market in 2019 is $7,219.3 million.
A. The adoption of prostate cancer treatment is expected to increase due to Significant increase in prevalence of prostate cancer, rise in geriatric population, surge in awareness among people towards prostate cancer treatment, increase in demand for prostate cancer treatment products, and rise in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings majorly driving the market growth
A. The base year calculated in the report is 2018.
A. Yes, Bayer AG is profiled in the report.
A. Emerging countries of Asia-Pacific region are growing at a growth% of 6.6%. Japan, China, Australia, India, South Korea are expected grow at a CAGR of 6.4%, 7.6%, 5.7%, 7.2%, 6.0%, respectively.
A. The North America market held a major share in the prostate cancer treatment market in 2018 and is expected to continue the trend in the forecasting period. This is attributed to surge in awareness among the population regarding early screening of cancer, increased adoption of prostate cancer treatment drugs, availability of premiere chemotherapy treatment options, and rise in non-government & government initiatives to promote healthcare are driving the prostate cancer treatment in North America
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
